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Background: Schizophrenia and bipolar disorder are chronic debilitating disorders that are often treated with
second-generation antipsychotic agents, such as aripiprazole, quetiapine, and ziprasidone. While patients who are
hospitalized for schizophrenia and bipolar disorder often receive these agents at discharge, comparatively little
information exists on subsequent patterns of pharmacotherapy.
Methods: Using a database linking hospital admission records to health insurance claims, we identified all patients
hospitalized for schizophrenia (ICD-9-CM diagnosis code 295.XX) or bipolar disorder (296.0, 296.1, 296.4-296.89)
between January 1, 2001 and September 30, 2008 who received aripiprazole, quetiapine, or ziprasidone at
discharge. Patients not continuously enrolled for 6 months before and after hospitalization (“pre-admission” and
“follow-up”, respectively) were excluded. We examined patterns of use of these agents during follow-up, including
adherence with treatment (using medication possession ratios [MPRs] and cumulative medication gaps [CMGs]) and
therapy switching. Analyses were undertaken separately for patients with schizophrenia and bipolar disorder,
respectively.
Results: We identified a total of 43 patients with schizophrenia, and 84 patients with bipolar disorder. During the
6-month period following hospitalization, patients with schizophrenia received an average of 101 therapy-days with
the second-generation antipsychotic agent prescribed at discharge; for patients with bipolar disorder, the
corresponding value was 68 therapy-days. Mean MPR at 6 months was 55.1% for schizophrenia patients, and 37.3%
for those with bipolar disorder; approximately one-quarter of patients switched to another agent over this period.
Conclusions: Medication compliance is poor in patients with schizophrenia or bipolar disorder who initiate
treatment with aripiprazole, quetiapine, or ziprasidone at hospital discharge.
Keywords: Schizophrenia, Bipolar disorder, Antipsychotic agents, Utilization, Healthcare costsBackground
Schizophrenia is a chronic, debilitating mental disorder
that affects approximately 1% of all persons in the
US [1]. Symptoms include – but are not limited to–
hallucinations, delusions, movement disorders, cogni-
tive impairment, and lack of pleasure in everyday life.
Onset of schizophrenia typically occurs before the age* Correspondence: aberger@pai2.com
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reproduction in any medium, provided the orof 45 years; it is equally likely to affect men and women
as well as members of all ethnic groups [2]. Anti-
psychotic drugs are the mainstay of treatment. Older
medications, including haloperidol and chlorpromazine,
often cause acute and chronic extrapyramidal side effects
(e.g., rigidity, tremors, tardive dyskinesia). Second-
generation (often termed “atypical”) antipsychotic drugs
infrequently induce these side effects.
Bipolar disorder, which is similarly debilitating, has
been estimated to affect about 1% of persons in the US
[3]. It is characterized by dramatic mood swings—fromLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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poor judgment, provocative and aggressive behavior) to
depressive states (e.g., persistent sad mood, feelings of
guilt, loss of interest in activities once enjoyed), and then
back again, typically with periods of normal mood in
between. Long-term therapy with “mood stabilizers”
(e.g., lithium, valproate, lamotrigine) is often used to control
the disease. However, other medications, including second-
generation antipsychotics (SGAs), are often used on a
short-term basis to treat “breakthrough” episodes of mania
or depression.
While SGAs generally are considered to be better tol-
erated than older agents, such as haloperidol and chlor-
promazine [4-6], their side effects--including weight
gain, increased serum prolactin levels, hyperglycemia,
and diabetes--can lead to therapy discontinuation, re-
sulting in an increased risk of relapse, higher utilization
of inpatient services, and higher costs of care [7]. SGAs
also have been associated with an increased risk of death
in older patients with dementia [8]. (Patients taking clo-
zapine are also at risk of agranulocytosis.) Results from a
large randomized trial in patients with schizophrenia
sponsored by the National Institute of Mental Health
(Clinical Antipsychotic Trials of Intervention Effective-
ness [CATIE]) [9] reported that “overall effectiveness” (as
measured by discontinuation at 18 months) was similar
between the first-generation antipsychotic, perphenazine,
and three of the four SGAs that were studied (risperi-
done, quetiapine, ziprasidone) (the fourth SGA in
CATIE, olanzapine, had a significantly lower rate of dis-
continuation [64% vs 75% for perphenazine], albeit still
high in absolute terms).
In this study, we examine patterns of pharmacotherapy
among patients who were hospitalized for schizophrenia
or bipolar disorder and received aripiprazole, quetiapine,
or ziprasidone at discharge. We focused attention on ari-
piprazole, quetiapine, or ziprasidone, as we believe these
SGAs are relatively similar with respect to their adverse
event profiles. Olanzapine and risperidone were ex-
cluded due to much higher reported rates of weight gain
with the former, and extrapyramidal symptoms (EPS)
with the latter [8].
Methods
Data source
Data for this study were obtained from a unique linkage be-
tween the Truven (formerly Thomson Reuters) MarketScanW
Commercial Claims and Encounters Database (a health
insurance claims database) and the Truven MarketScanW
Hospital Drug Database (an admission-level database).
The MarketScan Commercial Claims and Encounters
Database is comprised of paid institutional, provider,
and retail pharmacy claims from a variety of private
insurers, representing healthcare services provided toapproximately 10 million persons annually in the US.
This database contains information on patient demo-
graphics and eligibility, inpatient and outpatient diagno-
ses (in International Classification of Diseases, 9th edition
[ICD-9-CM] format), inpatient and outpatient procedures
(in ICD-9-CM, Physician Current Procedural Terminology,
4th edition [CPT-4], and Health Care Financing Adminis-
tration Common Procedure Coding System [HCPCS]
formats), drugs dispensed in an outpatient setting (using
National Drug Codes) (NDC), and dates of service for all
medical services and drugs. All data can be arrayed longitu-
dinally to provide a detailed profile of the medical and
pharmacy services used by each person over time.
The MarketScan Hospital Drug Database contains
admission-level information extracted from hospital
decision-support and/or cost-accounting systems on
about 3 million discharges annually from approximately
150 US, short-term, general, acute-care hospitals. For each
admission, the database includes (but is not limited to)
information on: (1) patient demographics (age, gender);
(2) principal and secondary diagnoses (in ICD-9-CM for-
mat); (3) principal and secondary procedures (in ICD-
9-CM format); (4) primary payer; (5) length of stay; (6)
day-of-stay data; (7) drug utilization; (8) discharge status
and destination; (9) department charge detail; and (10)
total inpatient charges.
All patient identifiers in both databases have been
fully encrypted, and both databases are fully compliant
with the Health Insurance Portability and Accountabil-
ity Act of 1996 (HIPAA). Since both databases were fully
de-identified and our research was retrospective, ethics
approval was unnecessary and therefore was not sought.
Information from the two databases was linked prior
to the analysis. This linkage permitted us to examine
patient characteristics in the period prior to initial hos-
pitalization, and also allowed for more complete ascer-
tainment of the use of SGAs. Data for this study spanned
the period January 1, 2001 through September 30, 2008
(“study period”).
Study sample
Using the MarketScan claims database, two study
cohorts were constituted. The first consisted of all
patients with evidence of any hospital admission with a
principal diagnosis of schizophrenia (ICD-9-CM diagno-
sis code 295.XX) during the study period (“schizophrenia
cohort”); the second, all patients with evidence of
any hospital admission for bipolar mania (296.0, 296.1,
296.4-296.89) during the same period (“bipolar cohort”).
Information for these selected patients was then
extracted from the Hospital Drug Database, and data
from the two files were then merged. Patients in the
healthcare claims database who could not be linked to
the admission-level database were dropped from the
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was focused on those who received oral ziprasidone, ari-
piprazole, or quetiapine on their day of hospital dis-
charge or the immediately preceding one (i.e., as their
discharge medication).
Patients not continuously enrolled for 6 months prior
to and following their hospital admission (“pre-admission”
and “follow-up”, respectively) were excluded. Attention
was limited to the first “qualifying” hospitalization only
if patients had more than one. We excluded patients if
they: (1) received clozapine any time during the study
period; (2) were enrolled in an insurance plan with a
mental health “carve-out” (and thus were likely to have
incomplete data on healthcare services received for the
treatment of mental disorders); (3) were aged <18 years
as of the date of hospital admission; (4) had any health-
care encounters with a diagnosis of epilepsy (ICD-9-CM
diagnosis codes 345.1, 345.4, 345.5) anytime prior to the
qualifying hospital admission (antiepileptics are some-
times used as mood stabilizers); or (5) had evidence of
both schizophrenia and bipolar disorder during the
study period.
All information from both data systems were then
compiled for all patients in the study sample from the
beginning of the 6-month pre-admission period to the
end of the 6-month follow-up period.
Measures and analyses
The demographic and clinical characteristics of study
subjects were examined, including their age, sex, plan
type, geographic region, and the prevalence of selected
comorbidities (Table 1), based on information from the
qualifying admission and the 6-month pre-admission
period. Patients were assumed to have a particular
comorbidity if they had either one or more hospitaliza-
tions, or two or more outpatient claims at least 30 days
apart, during the pre-admission period with a correspond-
ing diagnosis code. Levels of utilization of antipsychotics
and other psychotropic medications during the 6-month
pre-admission period also were examined, along with total
healthcare costs. We also examined selected characte-
ristics of the hospitals to which patients were admitted
(e.g., number of beds, teaching status).
Patterns of use of study agents were examined during
the follow-up period, including adherence and therapy
switching. Adherence was examined using medication
possession ratios (MPRs) and cumulative medication
gaps (CMGs). MPR was calculated as the ratio of the
total number of therapy-days supplied during follow-up
(beginning with day of hospital discharge, and ending
with last day of follow-up) to the total number of calen-
dar days in follow-up, which was the same for each pa-
tient in the study sample (i.e., 183 days). (Therapy-days
that extended beyond the last day of follow-up weretruncated as of this date.) CMG was calculated as the
ratio of the difference between the total number of days
of follow-up minus the total number of therapy-days, to
the total number of days of follow-up.
Therapy switching, which has been reported to be
associated with an increased likelihood of emergency
room encounters, hospital admissions, and higher health-
care costs [10,11], was defined as receipt of a “new”
antipsychotic following initiation of discharge therapy
(i.e., one not used during either the pre-admission period
or the qualifying admission) without any evidence of
receipt of the initial study agent ≥60 days following treat-
ment initiation with the “new” one. The date of therapy
switching was assumed to be the date of first receipt of
the new antipsychotic.
Use of other psychotropic medications during follow-
up was examined in terms of the numbers of patients
with any prescriptions for such therapies as well as the
numbers of prescriptions for—and therapy-days with—
these medications. Medications of interest included: (1)
other antipsychotics, including other SGAs (e.g., olanza-
pine, risperidone), and all others (e.g., flupenthixol, halo-
peridol, perphenzine, thioridazine); (2) mood stabilizers
(e.g., lithium, antiepileptics); (3) antidepressants (including
selective-serotonin reuptake inhibitors [SSRIs], serotonin-
norepinephrine reuptake inhibitors [SNRIs], tricyclic
antidepressants [TCAs], monoamine oxidase [MAO] in-
hibitors, mirtazpine, nefazodone, buproprion); and (4)
sedatives/hypnotics (e.g., benzodiapines, amobarbital,
zolpidem).
Simple descriptive statistics (e.g., frequency counts,
percentages, means, medians, SD) were used to describe
each measure. Kaplan-Meier methods were used to de-
pict the incidence of therapy switching. Significance
testing was not undertaken as there were no a priori
hypotheses (i.e., all analyses are descriptive in nature).
All analyses were done separately for the schizophrenia
and bipolar cohort, respectively. All analyses were con-
ducted using PC-SASW v.9.1.3.
Results
Schizophrenia cohort
A total of 228 patients were identified with at least one
admission for the treatment of schizophrenia during the
study period; after applying all remaining study entry
criteria, the total number of patients who qualified for
entry into the study was 43 (Table 2, Figure 1). Mean
(SD) age of patients with schizophrenia was 46.1 (13.0)
years and 58.1% were women (Table 3). A total of 67.4%
of patients had evidence of comorbid mental disorders,
including depressive disorders (39.5%), other psychoses
(25.6%) and alcohol/drug abuse (20.9%); 23.3% had evi-
dence of diabetes. At hospital discharge, 30.2% of
patients received aripiprazole; 34.9%, quetiapine; and
Table 1 Diagnoses (in ICD-9-CM format) used to identify comorbidities of interest
Comorbidity ICD-9-CM Diagnosis Codes
Depressive disorders 311, 296.2X, 296.3X, 296.5X, 296.82, 300.4, 298.0, 309.0, 309.28, 309.1
Dementia 290.XX, 291.2X, 310.9X, 331.0
Anxiety disorders 300.XX, 301.XX, 309.21
Post-traumatic stress disorder (PTSD) 309.81, 308.XX
Insomnia 780.50, 780.51, 780.53








Chronic obstructive pulmonary disease (COPD) 496
Cerebrovascular disease 430-438.XX
Coronary heart disease 410-414.XX
Dyslipidemia 272.4
Alcohol/drug abuse 303-305.XX
Suicide/self-harm attempts 300.9, 959.9, E950.X-E959.X
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schizophrenia, no patients received olanzapine, 3 (6.9%)
patients received risperidone, and 9 (20.9%) patients
received other antipsychotics, most often haloperidol
(n = 7 [16.3%]). Mean (SD) duration of therapy with the
three agents of interest (i.e., aripiprazole, quetiapine,
ziprasidone) during initial hospitalization for schizophre-
nia was 7.8 (6.0) days; the mean (SD) cost was $6512
($7666).
During the 6-month follow-up period, study subjects
averaged 7.2 (7.4) prescriptions for the study agentTable 2 Sample selection
Criteria
Total number of patients with ≥1 inpatient admissions for treatment of
condition of interest* during study period** and
Received oral ziprasidone, ariprazole, or quetiapine on the day of discharge o
immediately preceding one and
≥6 months enrollment prior to “qualifying” admission and
≥6 months enrollment subsequent to date of discharge of “qualifying” admi
Had no evidence of receipt of clozapine at any time during study period and
Were not enrolled in insurance plan with mental health “carve out” and
Were aged ≥18 years as of date of qualifying hospital admission and
Had no evidence of epilepsy prior to qualifying admission and
Had no evidence of other condition of interest* during study period
*Either schizophrenia or bipolar disorder.
*For patients with multiple such admissions, only the first such admission will be exprescribed at discharge, spanning 100.9 (69.0) therapy-
days; mean MPR and CMG were 55.1% (37.7%) and
44.9% (37.7%), respectively (Table 4). Eighty-four percent
of patients filled at least one prescription for the study
agent prescribed at discharge. Twenty-six percent of
patients had switched to another antipsychotic agent by
6 months; most instances of therapy switching occurred
within 3 months of discharge from the qualifying hos-
pitalization (Figure 2).
Use of psychotropic medications during follow-up was
common. Patients averaged 8.7 (8.5), 2.1 (4.8), 5.2 (6.5),Number of Patients in










amined; study period spans the period January 1, 2001 to September 30, 2008.
≥1 Admissions for treatment 
of schizophrenia during study 
period
N=228
≥1 Admissions for treatment 
of bipolar disorder during 
study period
N=389
Exclude admissions (N=138) without receipt of 
medications of interest on day of discharge or 
immediately preceding one
Exclude admissions (N=220) without receipt of 
medications of interest on day of discharge or 
immediately preceding one
Patients receiving oral 
ziprasidone, aripiprazole, or 
quetiapine 
N=90
Patients receiving oral 
ziprasidone, aripiprazole, or 
quetiapine 
N=169
Exclude due to enrollment (N=38):
-<6 months pre-admission (N=24)
-<6 months post-admission (N=14)
Exclude due to enrollment (N=59):
-<6 months pre-admission (N=42)
-<6 months post-admission (N=17)
Patients with minimum 
enrollment criteria 
N=52
Patients with minimum 
enrollment criteria 
N=110
Exclude due to medications/insurance (N=7):
-Clozapine use (N=5)
-Mental health "carve out" (N=2)
Exclude due to medications/insurance (N=4):
-Clozapine use (N=1)
-Mental health "carve out" (N=3)
Patients without clozapine 
use/mental health "carve out"
N=45
Patients without clozapine 
use/mental health "carve out"
N=106
Exclude due to age/other conditions (N=2):
-Aged <18 years (N=1)
-Evidence of epilepsy or bipolar disorder (N=1)
Exclude due to age/other conditions (N=22):
-Aged <18 years (N=19)





Figure 1 Sample selection criteria.
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cluding study agents), other antipsychotics, mood stabiliz-
ers, antidepressants, and sedatives/hypnotics, respectively;
corresponding values for therapy-days were 162.9 (105.7),
31.0 (80.1), 114.8 (132.1), 86.6 (93.1), and 27.7 (66.3),
respectively.
Bipolar disorder cohort
A total of 389 patients were identified who had at least
one admission for the treatment of bipolar disorder dur-
ing the study period; after applying all remaining study
entry criteria, the total number of patients who qualified
for entry into the study was 84 (Table 2, Figure 1). Mean
(SD) age of patients with bipolar disorder was 44.5
(15.0) years, and 73.8% were women (Table 3). Most
patients (82.1%) had evidence of other mental disorders,
including depressive disorders (51.2%), anxiety disorders
(36.9%), other psychoses (22.6%), and alcohol/drug abuse
(14.3%); 15.5% had evidence of diabetes. At hospital dis-
charge, 15.5% of patients received aripiprazole; 56.0%,
quetiapine; and 28.6%, ziprasidone. During the initial
hospitalization for bipolar disorder, no patients received
olanzapine, 6 (7.1%) patients received risperidone, and 11
(13.1%) patients received other antipsychotics, most oftenmesoridazine (n = 4 [4.8%]) or haloperidol (n = 3 [3.6%]).
Mean (SD) duration of therapy with the three agents of
interest (i.e., aripiprazole, quetiapine, ziprasidone) during
initial hospitalization for bipolar disorder was 4.6 (4.3)
days; the mean (SD) cost was $6663 ($8900).
During the 6-month period of follow-up, these pa-
tients averaged 4.2 (3.5) prescriptions for the study agent
prescribed at discharge, spanning 68.3 (60.5) therapy-
days; mean MPR and CMG were 37.3% (33.1%) and
62.7% (33.1%), respectively (Table 4). Seventy-four per-
cent of patients filled at least one prescription for the
study agent prescribed at discharge. Twenty-six percent
of patients had switched to another antipsychotic agent
by 6 months; most instances of therapy-switching oc-
curred within 3 months of discharge from the qualifying
hospitalization (Figure 2).
Use of psychotropic medications during follow-up was
common. Patients averaged 4.6 (2.8), 0.7 (1.6), 4.4 (3.6),
2.0 (2.7), and 2.0 (2.9) pharmacy dispenses for SGAs (in-
cluding study agents), other antipsychotics, mood stabiliz-
ers, antidepressants, and sedatives/hypnotics, respectively;
corresponding values for therapy-days were 111.1 (103.8),
16.0 (47.2), 118.3 (121.0), 56.2 (75.8), and 47.6 (96.1),
respectively.






(N = 43) (N= 84)
Mean (SD) age 46.1 (13.0) 44.5 (15.0)
Female 25 (58.1) 62 (73.8)
Payer type
HMO 3 (7.0) 9 (10.7)
POS 21 (48.8) 48 (57.1)
PPO 5 (11.6) 12 (14.3)
Other/unknown 14 (32.6) 15 (17.9)
Comorbidities
Mental disorders
Depressive disorders 17 (39.5) 43 (51.2)
Dementia 0 (0.0) 0 (0.0)
Anxiety disorders 4 (9.3) 31 (36.9)
PTSD 0 (0.0) 0 (0.0)
Insomia 0 (0.0) 0 (0.0)
Other psychoses 11 (25.6) 19 (22.6)
Bulinia nervosa 0 (0.0) 0 (0.0)
Impulse-control disorder 0 (0.0) 0 (0.0)
Chronic fatigue syndrome 0 (0.0) 0 (0.0)
Alcohol/drug abuse 9 (20.9) 12 (14.3)
Suicide/self harm attempts 0 (0.0) 0 (0.0)
Any of above 29 (67.4) 69 (82.1)
All other
Diabetes 10 (23.3) 13 (15.5)
Hypertension 9 (20.9) 21 (25.0)
Obesity 3 (7.0) 3 (3.6)
Arthritis 2 (4.7) 2 (2.4)
COPD 2 (4.7) 3 (3.6)
Cerebrovascular disease 1 (2.3) 1 (1.2)
Coronary heart disease 4 (9.3) 4 (4.8)
Dyspilidemia 0 (0.0) 1 (1.2)
Characteristics of admitting hospital**
Number of beds
≤200 4 (9.3) 8 (9.5)
201-300 5 (11.6) 31 (36.9)
>300 32 (74.4) 45 (53.6)
Non-teaching facilities 37 (86.0) 78 (92.9)
Receipt during pre-admission period of
Antipsychotics
Atypicals 40 (93.0) 65 (77.4)
Others 17 (39.5) 12 (14.3)
All of the above 41 (95.3) 66 (78.6)
All other psychotropic
medications
33 (76.7) 78 (92.9)
Table 3 Demographic and clinical characteristics, by
study cohort* (Continued)
Total costs, $
Mean (SD) total pre-admission costs, $ 13,696 (9,517) 13,747 (11,236)
*Unless otherwise indicated, all values are number of patients (%).
provider organization; PTSD: Post-traumatic stress disorder; COPD: Chronic
obstructive pulmonary disorder.
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HMO: Health-maintenance organization; POS: Point of service; PPO: Preferred-Discussion
In our study, patients with schizophrenia or bipolar dis-
order who were recently discharged from the hospital
were found to have poor adherence over time with aripi-
prazole, quetiapine, and ziprasidone. Those with schizo-
phrenia received medication sufficient to cover only aboutTable 4 Magnitude of use of initial therapy during follow-
up, by study cohort
Schizophrenia Cohort Bipolar Cohort
(N= 43) (N= 84)
Prescriptions
Mean (SD) 7.2 (7.4) 4.2 (3.5)
Median (IQR) 5 (3, 8) 3 (2, 6)
Therapy-days
Mean (SD) 100.9 (69.0) 68.3 (60.5)
Median (IQR) 121 (31,166) 46 (31,115)
MPR
<10% 8 (18.6) 20 (23.8)
10-20% 6 (14.0) 22 (26.2)
21-30% 1 (2.3) 0 (0.0)
31-40% 2 (4.7) 7 (8.3)
41-50% 0 (0.0) 11 (13.1)
51-60% 2 (4.7) 2 (2.4)
61-70% 4 (9.3) 6 (7.1)
71-80% 4 (9.3) 3 (3.6)
81-90% 6 (14.0) 3 (3.6)
91-100% 10 (23.3) 10 (11.9)
Mean (SD) 55.1 (37.7) 37.3 (33.1)
CMG
<10% 11 (25.6) 10 (11.9)
10-20% 8 (18.6) 4 (4.8)
21-30% 1 (2.3) 2 (2.4)
31-40% 4 (9.3) 6 (7.1)
41-50% 2 (4.7) 13 (15.5)
51-60% 0 (0.0) 1 (1.2)
61-70% 2 (4.7) 6 (7.1)
71-80% 1 (2.3) 0 (0.0)
81-90% 6 (14.0) 22 (26.2)
91-100% 8 (18.6) 20 (23.8)
Mean (SD) 44.9 (37.7) 62.7 (33.1)
*Unless otherwise indicated, all values are number of patients (%).
















Schizophrenia Cohort Bipolar Cohort
Figure 2 Incidence of therapy switching during follow-up, by study cohort.
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while those with bipolar disorder received medication suf-
ficient to cover only about 37% of their follow-up days.
Approximately one in four patients had evidence of
therapy switching during the 6-month follow-up period.
Noncompliance is an important predictor of hospi-
talization risk. Following inpatient treatment and dis-
charge from the community, many patients become
poorly compliant with therapy [12,13]. Several reasons for
poor compliance have been hypothesized, including disease
symptoms (e.g., grandiosity, paranoia, problems with ac-
curate recall), treatment-emergent side effects, substance
abuse, lack of support systems to encourage medication
compliance, psychostressors, and poor patient-provider
relationships [14,15]. Previous reports suggest that more
than one-half of all patients with schizophrenia become
noncompliant with their medication regimen within one
month of discharge from hospital [15]; by 2 years following
discharge, about 75% are noncompliant [15-17]. Among
patients with bipolar disorder, compliance is also low. In
one retrospective analysis of healthcare claims data, Lage
and Hassan report that 62% of patients with bipolar dis-
order newly started on antipsychotics had MPRs ≤50%,
and that mean MPR was 41.7% [18]. Rates of medication
adherence were low in our study too.
We limited our attention to aripiprazole, quetiapine, or
ziprasidone, as we believed these three SGAs to be rela-
tively similar with respect to their adverse event profiles.
Olanzapine and risperidone were excluded due to muchhigher reported rates of weight gain with the former, and
extrapyramidal symptoms (EPS) with the latter [8]. Our
results suggest that adherence is not substantially better
with these agents than with other SGAs (e.g., rates of
discontinuation in the CATIE study ranged from 64%
[olanzapine] to 82% [quetiapine]) [19]. We note, however,
that our study sample was small, which limits the
generalizability of our findings. Further study is needed
to better understand patterns of “real-world” adherence
among patients prescribed SGAs upon discharge from hos-
pital for schizophrenia and bipolar disorder, respectively.
This study has a few key limitations. For one, our sam-
ple size was small, principally because the study dataset
was created by linking information from a health insur-
ance claims database with data from a large inpatient
data warehouse. Compounding this limitation was our
decision to limit the study sample to patients with at
least 6 months of eligibility for medical and drug bene-
fits before and after the “qualifying” hospitalization, and
to exclude patients with evidence of both schizophrenia
and bipolar mania. Accordingly, the generalizability of
our findings to all patients hospitalized for schizophrenia
or bipolar disorder who are subsequently discharged on
SGAs is unknown. On a related note, while prior re-
search in both schizophrenia and bipolar disorder has
established an inverse correlation between levels of ad-
herence with antipsychotic medications and risk of re-
lapse [20-32], the relatively small number of patients in
our study precluded an examination of this question.
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most of the information on patterns of utilization of study
agents during follow-up—only allows the identification
of prescription drugs dispensed by retail pharmacies
(i.e., filled prescriptions and their associated therapy-
days). We could not ascertain whether medications that
were dispensed were actually taken. Thus, our estimates
may represent an upper bound for the amount of medi-
cation actually taken. On the other hand, it should be
noted that patients are sometimes discharged from hos-
pital with a small supply (e.g., 3 days) of medication to
insure continued use until they are able to fill a prescrip-
tion at a retail pharmacy. Unfortunately, the database
does not contain information on professional samples
dispensed at hospital discharge. In our study, 39%, 56%,
and 69% of patients in the schizophrenia cohort filled
their first prescription for study agents within one,
six, and 14 days of discharge from their qualifying
hospitalization, respectively; corresponding values for
patients in the bipolar cohort were 61%, 81%, and
82%, respectively. It is reasonable to assume that most
of these patients were intent on continuing with the study
agent received at discharge. Accordingly, our reliance on
therapy-days as noted on paid claims from retail phar-
macies likely understates the amount of medication actu-
ally taken. Further study is needed to better understand
the degree to which patients with schizophrenia and/or
bipolar disorder adhere to discharge therapy.
Finally, as with all database studies, there may be
errors of omission and commission in coding. However,
the case-finding algorithm (i.e., hospitalization with a
principal diagnosis of schizophrenia or bipolar disorder,
and initiation of SGA treatment at discharge) used in
this analysis likely minimized the inclusion of patients
who did not have schizophrenia or bipolar disorder
therefore, the specificity of this algorithm is likely high.Conclusions
In conclusion, this study suggests that adherence is a sub-
stantial problem in patients hospitalized for schizophrenia
and bipolar disorder who are discharged on second-
generation antipsychotics. Further research is needed to
better understand the reason(s) for these poor levels of
adherence among this group of high-risk patients, and
the degree to which nonadherence may be associated
with higher levels of healthcare utilization and costs fol-
lowing hospital discharge, including rehospitalization.
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